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OBJECTIVES We sought to determine whether clopidogrel is at least as efficacious as ticlopidine.
BACKGROUND Several trials have supported the enhanced safety and tolerability of clopidogrel compared
with ticlopidine after coronary stent deployment. However, none of these individual trials
were powered to detect possible differences in the efficacy for reducing ischemic end points.
METHODS Published data from trials and registries that compared clopidogrel with ticlopidine in
patients receiving coronary stents were pooled, and a formal meta-analysis was performed.
The rate of 30-day major adverse cardiac events (MACE), as defined in each trial, was used
as the primary end point.
RESULTS There were a total of 13,955 patients. The pooled rate of major adverse cardiac events was
2.10% in the clopidogrel group and 4.04% in the ticlopidine group. After adjustment for
heterogeneity in the trials, the odds ratio (OR) of having an ischemic event with clopidogrel,
as compared with ticlopidine, was 0.72 (95% confidence interval [CI] 0.59 to 0.89, p 
0.002). Mortality was also lower in the clopidogrel group compared with the ticlopidine
group—0.48% versus 1.09% (OR 0.55, 95% CI 0.37 to 0.82; p  0.003).
CONCLUSIONS Based on all available evidence from randomized clinical trials or registries, clopidogrel, in
addition to better tolerability and fewer side effects, is at least as efficacious as ticlopidine in
reducing MACE. This finding may be due to the more rapid onset of an antiplatelet effect
seen with the loading dose of clopidogrel, which was used in most of these studies, or to better
patient compliance with clopidogrel therapy. Therefore, clopidogrel plus aspirin should
replace ticlopidine plus aspirin as the standard antiplatelet regimen after stent
deployment. (J Am Coll Cardiol 2002;39:9–14) © 2002 by the American College of
Cardiology
The preferred method of percutaneous coronary revascular-
ization is stenting. Compared with balloon angioplasty,
coronary stenting has been proven to decrease rates of target
vessel revascularization for a broad variety of lesion types
(1–10). However, there is a risk created by placing a foreign
object in the coronary vasculature—namely, stent thrombo-
sis.
Antiplatelet therapy with aspirin plus the adenosine
diphosphate (ADP) antagonist ticlopidine has been shown
to be superior to either aspirin alone or aspirin plus
anticoagulation with warfarin after coronary stent deploy-
ment (11). However, ticlopidine is associated with up to a
2.4% rate of neutropenia (white blood cell count 1,200/
mm3), which can be a life-threatening complication (11). In
addition, thrombotic thrombocytopenic purpura (TTP) is
estimated to occur in 1 in 4,800 treated patients (12).
The Clopidogrel versus Aspirin in Patients at Risk of
Ischemic Events (CAPRIE) study demonstrated that the
newer ADP antagonist clopidogrel was more efficacious
than aspirin in preventing ischemic events in patients with
established atherosclerosis (13). This benefit is amplified
further in high-risk subgroups (14). Clopidogrel is much
safer than ticlopidine; neutropenia is no more likely to occur
in patients taking clopidogrel than in those taking aspirin,
with a 0.10% rate of neutropenia (neutrophils 1,200/
mm3) observed in CAPRIE (13). In addition, clopidogrel is
better tolerated; the onset of action is more rapid; and the
once-a-day dosing regimen is more convenient. Further-
more, in the U.S., clopidogrel is 20% less expensive than
ticlopidine, although this cost differential may vary in other
parts of the world. These facts have led many interventional
cardiologists to switch from ticlopidine plus aspirin to
clopidogrel plus aspirin after stenting, although some have
remained critical of this substitution in the absence of a
large comparative data set demonstrating equivalent efficacy
(15–17).
Despite the existence of multiple, randomized clinical
trials and single-center registries comparing clopidogrel plus
aspirin versus ticlopidine plus aspirin, none was individually
powered to assess the comparative efficacy of clopidogrel
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versus ticlopidine. Therefore, by aggregating all trial and
registry data, we sought to determine whether clopidogrel
plus aspirin would be at least as effective as ticlopidine plus
aspirin in reducing ischemic events in patients receiving
coronary stents.
METHODS
A MEDLINE search was performed to identify all pub-
lished, English-language studies through December 2000
that compared clopidogrel plus aspirin versus ticlopidine
plus aspirin. The medical subject headings and key words
used were clopidogrel, ticlopidine and stents. In addition,
relevant abstracts and presentations from the annual meet-
ings in 1999 and 2000 of the American Heart Association,
the American College of Cardiology, the European Society
of Cardiology and Transcatheter Cardiovascular Therapeu-
tics were identified. Three randomized clinical trials and
seven single-center registries comparing clopidogrel plus
aspirin versus ticlopidine plus aspirin have been presented or
published. When the results were published only in abstract
form or presented orally or in a poster, the data were verified
with the primary investigator.
The three randomized trials (18–20) were the CLopi-
dogrel ASpirin Stent International Cooperative Study
(CLASSICS), the Ticlid Or Plavix Post-Stent (TOPPS)
trial and the trial performed by Mu¨ller et al. There were
differences in loading doses and length of therapy among
these three trials. CLASSICS, which was the only double-
blinded evaluation, utilized a loading dose of clopidogrel in
one arm of the study, and therapy was administered within
6 h of completion of the procedure and lasted for 28 days.
The TOPPS trial used loading doses of both ticlopidine and
clopidogrel, given after the procedure, with therapy contin-
ued for 14 days. Mu¨ller et al. (18) used a 500-mg loading
dose for the ticlopidine arm only, and therapy was com-
menced immediately after the procedure and continued for
28 days.
The seven single-center registries were from the Cleve-
land Clinic Foundation, the Lenox Hill Heart and Vascular
Institute, the Mayo Clinic, North Memorial Hospital,
Southern Illinois University, the Washington Hospital
Center and the Wessex Cardiothoracic Centre (21–27).
There were differences among the registries (and sometimes
within the registries) as to whether patients were pretreated
with a thienopyridine before the procedure, whether loading
doses were administered and whether the length of therapy
was 14 or 28 days.
The results from these 10 studies were pooled. Thirty-day
major adverse cardiac events (MACE), as defined in each
trial, served as the prespecified primary end point, and
all-cause mortality was the prespecified secondary end point.
The MACE consisted of death, myocardial infarction (MI),
target vessel revascularization (TVR) or subacute stent
thrombosis (SAST) in all studies except CLASSICS and
those performed at the Cleveland Clinic and North Memo-
rial Hospital, which did not report SAST. For MACE,
there was no double counting of events. In addition, the
rates of MI, TVR and SAST, as defined in each trial, were
pooled, and Pearson chi-square values were calculated for
each of these individual end points. For MACE and
mortality, to address the heterogeneity among the trials and
registries, a formal meta-analysis was performed by com-
bining the numbers of observed and expected events from
each trial using the Mantel-Haenszel test, as expressed by
Yusuf et al. (28). A fixed-effects model was used for this
tabular meta-analysis.
RESULTS
The majority of the trials and registries found a reduction in
the 30-day rate of MACE, as defined by each trial, with
clopidogrel versus ticlopidine. Figure 1 depicts the odds
ratio (OR) plot, with 95% confidence intervals (CIs) for the
rate of MACE. Overall, the pooled data from 13,955
patients showed an OR of 0.51 in favor of clopidogrel (95%
CI 0.42 to 0.63). This 50% risk reduction in the MACE
rate in those patients receiving clopidogrel plus aspirin
versus ticlopidine plus aspirin (2.10% vs. 4.04%) was statis-
tically significant (p 0.001). The reduction in the MACE
rate was seen in both the randomized clinical trial and the
registry data, but was only substantial and statistically
significant in the registries. The OR in favor of clopidogrel
in the randomized clinical trials was 0.90 (95% CI 0.57 to
1.44). The OR in favor of clopidogrel in the larger numbers
of patients in the registries was 0.45 (95% CI 0.36 to 0.57,
p  0.001).
Mortality. The majority of patients in the trials showed a
reduction in all-cause mortality with clopidogrel versus
ticlopidine (Fig. 2). The OR in favor of clopidogrel was 0.44
(95% CI 0.29 to 0.67). This 56% reduction in mortality in
those patients treated with clopidogrel and aspirin instead of
ticlopidine and aspirin (0.48% versus 1.09%) was statistically
significant (p  0.001). When confining the analysis to the
three randomized clinical trials, the OR in favor of clopi-
dogrel was 0.47 (95% CI 0.17 to 1.30, p  0.14). The
registry data produced an OR of 0.45 in favor of clopidogrel
(95% CI 0.28 to 0.70, p  0.001).
Abbreviations and Acronyms
ADP  adenosine diphosphate
CI  confidence interval
CLASSICS  CLopidogrel ASpirin Stent International
Cooperative Study
MACE  major adverse cardiac events
MI  myocardial infarction
OR  odds ratio
SAST  subacute stent thrombosis
TOPPS  Ticlid Or Plavix Post-Stent
TTP  thrombotic thrombocytopenic purpura
TVR  target vessel revascularization
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Individual end points. Myocardial infarction, TVR and
SAST data were defined differently for the trials included,
and not all trials collected data for each of these end points.
Thus, the actual numbers of patients available for analysis
for these particular end points were smaller than the number
of patients for the overall analysis. Nevertheless, all the
components of the MACE rate appeared to be affected
favorably by clopidogrel instead of ticlopidine (Fig. 3).
Meta-analysis. Using a technique of formal meta-analysis
to attempt to adjust for the heterogeneity among the trials
included, a reduction in the event rate was still evident for
both MACE and mortality. The OR for the rate of MACE
for clopidogrel was 0.72 (95% CI 0.59 to 0.89, p  0.002),
as compared with ticlopidine. The OR for the rate of
mortality was 0.55 in favor of clopidogrel (95% CI 0.37 to
0.82, p  0.003).
DISCUSSION
Stent deployment has been a major advance in interven-
tional cardiology. Few surgical procedures have undergone
as rigorous clinical evaluation as coronary stenting. The
Figure 1. The odds ratio (OR) plots with 95% confidence intervals (CIs) for the rate of 30-day major adverse cardiac events (MACE) for each of the trials
individually, as well as for the pooled data. Estimates to the left of the centerline reflect that clopidogrel was more effective; those to the right of the
centerline indicate that ticlopidine was more effective. The size of the boxes corresponds to the number of patients in the trial. Arrows indicate that the
limits of the CI extend beyond the graph. CCF  Cleveland Clinic Foundation; CLASSICS  CLopidogrel ASpirin Stent International Cooperative
Study; TOPPS  Ticlid Or Plavix Post-Stent.
Figure 2. The odds ratio (OR) plots with 95% confidence interval (CIs) for the rate of 30-day mortality. The boxes for the CLopidogrel ASpirin Stent
International Cooperative Study (CLASSICS) and North Memorial studies reflect directionality and sample size, but true ORs cannot be determined,
because both trials had an arm with a point estimate of zero. Arrows indicate that the limits of the CI extend beyond the graph. CCF  Cleveland Clinic
Foundation; TOPPS  Ticlid Or Plavix Post-Stent.
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results of numerous randomized clinical trials have demon-
strated conclusively the benefits of stenting in reducing both
urgent and elective TVR (1–10,29). This benefit in reducing
TVR during one-year follow-up extends across a broad
variety of lesion types.
Nevertheless, stent thrombosis is a major risk after
coronary stenting. Initial attempts to decrease stent throm-
bosis through pharmacologic means often involved complex
regimens of aspirin, heparin, dextran and warfarin, with
high rates of bleeding and extended hospital stays. The use
of high-pressure stent deployment and antiplatelet therapy
with aspirin and ticlopidine has dramatically reduced the
incidence of stent thrombosis (30,31). Aspirin plus ticlopi-
dine has been demonstrated to reduce MACE significantly
more than aspirin plus warfarin, with a decreased incidence
of bleeding. However, when stent thrombosis does occur, it
is typically accompanied by MI or death (32). Thus, any
measure to decrease stent thrombosis is warranted.
Risks of ticlopidine. Although ticlopidine plus aspirin is
clearly efficacious after coronary artery stenting, issues of
safety hamper the use of ticlopidine. Neutropenia, which
can be life threatening, can occur and necessitates periodic
measurement of the white blood cell count. In addition,
TTP rarely occurs with ticlopidine and, unless recognized
and treated promptly, may lead to death. Clopidogrel,
though also an ADP receptor antagonist, differs from
ticlopidine in its chemical structure, with an additional
methyl group. Furthermore, clopidogrel and ticlopidine
share no known common metabolites. The CAPRIE trial
demonstrated that the rate of neutropenia (1,200/mm3)
was negligible and was no higher with clopidogrel than with
aspirin (0.10% vs. 0.17%) (13). Although a recent case series
described 11 cases of TTP in patients receiving medications,
including clopidogrel, a true causal relationship could not be
established with certainty (33). Regardless, even if the cases
were due to clopidogrel, the incidence of TTP would still be
at least an order of magnitude less than that seen with
ticlopidine, with perhaps the same incidence as seen in the
general population.
The randomized CLASSICS trial showed that the pri-
mary safety end point favored clopidogrel over ticlopidine
(19). Clopidogrel was associated with less bleeding, fewer
hematologic complications and fewer cases of drug discon-
tinuation. However, CLASSICS was neither designed nor
powered to look at differences in efficacy. Nevertheless,
given the better safety and tolerability of clopidogrel, most
interventional cardiologists in the U.S. switched to a regi-
men of clopidogrel plus aspirin after coronary stenting,
often for a period of 30 days.
Clopidogrel versus ticlopidine. However, in this era of
evidence-based medicine, there was a level of uncertainty
regarding the comparative efficacy of clopidogrel versus
ticlopidine (15–17). None of the individual trials or regis-
tries comparing clopidogrel with ticlopidine was large
enough to conclusively demonstrate that clopidogrel was
equivalent to ticlopidine in efficacy. In addition, investiga-
tions of warfarin plus aspirin after coronary stenting con-
tinue, despite the accumulated randomized data supporting
ticlopidine plus aspirin (34). Thus, there was no consensus
in the worldwide interventional community regarding the
optimal antithrombotic regimen after stenting.
The present analysis demonstrates that compared with
aspirin plus ticlopidine, a regimen of aspirin plus clopidogrel
is associated with a decreased rate of MACE at 30 days.
There was a reduction in each of the individual components
of MACE. Most notable was a significant reduction in the
rate of all-cause mortality, evident in both the randomized
and registry data. Importantly, the decrease in death was
proportionate and consistent with the reduction in MI.
Although there was some heterogeneity between the ran-
domized trials and registries for the rate of MACE, perhaps
due to patient selection criteria in clinical trials, the mag-
nitude of reduction in mortality was similar for both types of
studies. Furthermore, the reduction in MACE and mortal-
Figure 3. The odds ratio plots with 95% confidence intervals (CIs) for the rates of the individual components of the composite end point. MACE  major
adverse cardiac events; MI  myocardial infarction; SAT  subacute stent thrombosis; TVR  target vessel revascularization.
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ity rates persists even after adjustment for heterogeneity
among the different trials and registries included.
Although the goal of this analysis was to demonstrate
similar efficacy between clopidogrel and ticlopidine, the
results strongly suggest superior efficacy of clopidogrel over
ticlopidine. In part, this finding may be due to better patient
compliance with clopidogrel, as demonstrated in the ran-
domized CLASSICS data. Likely, this effect is even larger
in clinical practice, outside the confines of a closely moni-
tored clinical trial. Due to nausea and vomiting, up to 20%
of patients have required discontinuation of ticlopidine in
placebo-controlled trials. In addition, ticlopidine’s onset of
action is longer than that of a loading dose of clopidogrel.
Previous work has shown that some cases of stent throm-
bosis occur early after the initiation of ticlopidine, presum-
ably before its full antiplatelet activity has been achieved
(35). Furthermore, the use of ticlopidine is sometimes
limited to only two weeks after coronary artery stenting,
whereas clopidogrel is often used for four weeks, perhaps
providing further protection against ischemic events. The
Clopidogrel for Reduction of Events During Observation
trial will determine the incremental benefits of a more
prolonged duration of therapy with clopidogrel after coro-
nary artery stenting. Selection of the optimal dual-
antiplatelet regimen has particular relevance now that vas-
cular brachytherapy is widely available. In this setting,
dual-antiplatelet therapy will be required for an extended
time, particularly if a new stent is placed. The subset of
patients from the Clopidogrel in Unstable angina to prevent
Recurrent ischemic Events trial who underwent stenting
will provide further information on the safety and utility of
an extended duration of clopidogrel therapy (36).
Study limitations. There are certain limitations to the
present analysis. Registry data were often not concurrent, in
that the data on patients taking ticlopidine were sometimes
obtained in a period before the collected data on patients
taking clopidogrel. In addition, registry data, due to its
nonrandomized nature, can be subject to confounding
variables, such as different rates of glycoprotein IIb/IIIa
inhibitor or device use. Thus, this analysis may overestimate
the treatment benefit seen with clopidogrel over ticlopidine.
Nevertheless, registry data do give an impression of the
applicability of clinical trial data in the “real world.” There
were different loading dose regimens used in the studies,
and this can potentially affect the results obtained with
either clopidogrel or ticlopidine. In addition, it was not
known which patients may have been pretreated with a
thienopyridine for a period of time. The definitions of some
of the components of MACE—namely, MI, TVR and
SAST—differed, and not all of these data were collected for
each trial. For example, not all trials collected routine
post-procedural creatine phosphokinase levels, and defini-
tions of stent thrombosis varied somewhat. Of course,
all-cause mortality was the one end point that was consis-
tent among trials and was therefore prespecified at the
outset of this analysis.
Conclusions. Compared with ticlopidine, clopidogrel is
associated with a decreased rate of 30-day MACE, includ-
ing all-cause mortality. In addition, clopidogrel is known to
be safer, better tolerated and more conveniently dosed than
ticlopidine and is also less expensive. Furthermore, the
comparatively favorable hematologic profile of clopidogrel
makes the possibility of its long-term use in secondary
prevention more acceptable than long-term ticlopidine ther-
apy. The beneficial effect of clopidogrel observed in this
analysis may be due to the more rapid onset of an antiplate-
let effect seen with the loading dose of clopidogrel used in
most of these studies, or to better patient compliance with
clopidogrel therapy. Based on this data set of almost 14,000
patients, it can be reasonably concluded that clopidogrel
plus aspirin is at least as effective as ticlopidine plus aspirin
in reducing adverse ischemic events, and, in fact, in addition
to its known better safety profile, clopidogrel appears to be
more efficacious than ticlopidine. Unless new, large and
definitive randomized clinical trials are performed, clopi-
dogrel plus aspirin should be regarded as the standard of
care for patients who have received coronary stents.
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